Hansoh Pharmac Hd 00001 Stock EBITDA
| 3KY Stock | EUR 2.14 0.02 0.93% |
HANSOH PHARMAC HD 00001 fundamentals help investors to digest information that contributes to HANSOH PHARMAC's financial success or failures. It also enables traders to predict the movement of HANSOH Stock. The fundamental analysis module provides a way to measure HANSOH PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HANSOH PHARMAC stock.
HANSOH |
HANSOH PHARMAC HD 00001 Company EBITDA Analysis
HANSOH PHARMAC's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current HANSOH PHARMAC EBITDA | 3.02 B |
Most of HANSOH PHARMAC's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HANSOH PHARMAC HD 00001 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, HANSOH PHARMAC HD 00001 reported earnings before interest,tax, depreciation and amortization of 3.02 B. This is 244.43% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The ebitda for all Germany stocks is 22.48% higher than that of the company.
HANSOH EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HANSOH PHARMAC's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HANSOH PHARMAC could also be used in its relative valuation, which is a method of valuing HANSOH PHARMAC by comparing valuation metrics of similar companies.HANSOH PHARMAC is rated below average in ebitda category among its peers.
HANSOH Fundamentals
| Return On Equity | 0.14 | |||
| Return On Asset | 0.063 | |||
| Profit Margin | 0.27 % | |||
| Operating Margin | 0.28 % | |||
| Shares Outstanding | 5.92 B | |||
| Shares Owned By Insiders | 81.92 % | |||
| Shares Owned By Institutions | 7.99 % | |||
| Price To Earning | 38.60 X | |||
| Revenue | 9.97 B | |||
| Gross Profit | 9.06 B | |||
| EBITDA | 3.02 B | |||
| Net Income | 2.57 B | |||
| Cash And Equivalents | 13.73 B | |||
| Cash Per Share | 2.32 X | |||
| Total Debt | 92.75 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 6.43 X | |||
| Book Value Per Share | 3.57 X | |||
| Cash Flow From Operations | 2.39 B | |||
| Earnings Per Share | 0.06 X | |||
| Number Of Employees | 10.78 K | |||
| Beta | 0.57 | |||
| Market Capitalization | 11.47 B | |||
| Z Score | 73.8 | |||
| Annual Yield | 0.01 % | |||
| Last Dividend Paid | 0.12 |
About HANSOH PHARMAC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HANSOH PHARMAC HD 00001's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HANSOH PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HANSOH PHARMAC HD 00001 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in HANSOH Stock
HANSOH PHARMAC financial ratios help investors to determine whether HANSOH Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HANSOH with respect to the benefits of owning HANSOH PHARMAC security.